vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $270.6M, roughly 1.1× Astera Labs, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs 12.8%, a 3.8% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs -6.4%). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 4.2%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ALAB vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $295.9M |
| Net Profit | $45.0M | $38.0M |
| Gross Margin | 75.6% | 64.6% |
| Operating Margin | 24.7% | 18.4% |
| Net Margin | 16.6% | 12.8% |
| Revenue YoY | 91.8% | -6.4% |
| Net Profit YoY | 82.0% | 68.3% |
| EPS (diluted) | $0.25 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $295.9M | ||
| Q3 25 | $230.6M | — | ||
| Q2 25 | $191.9M | $317.0M | ||
| Q1 25 | $159.4M | $316.2M | ||
| Q4 24 | $141.1M | $297.0M | ||
| Q3 24 | $113.1M | $289.5M | ||
| Q2 24 | $76.8M | $306.1M | ||
| Q1 24 | $65.3M | $303.4M |
| Q4 25 | $45.0M | $38.0M | ||
| Q3 25 | $91.1M | — | ||
| Q2 25 | $51.2M | $-17.7M | ||
| Q1 25 | $31.8M | $22.6M | ||
| Q4 24 | $24.7M | $34.9M | ||
| Q3 24 | $-7.6M | $33.6M | ||
| Q2 24 | $-7.5M | $40.6M | ||
| Q1 24 | $-93.0M | $49.1M |
| Q4 25 | 75.6% | 64.6% | ||
| Q3 25 | 76.2% | — | ||
| Q2 25 | 75.8% | 62.7% | ||
| Q1 25 | 74.9% | 67.9% | ||
| Q4 24 | 74.0% | 65.3% | ||
| Q3 24 | 77.7% | 63.2% | ||
| Q2 24 | 77.9% | 66.4% | ||
| Q1 24 | 77.4% | 67.4% |
| Q4 25 | 24.7% | 18.4% | ||
| Q3 25 | 24.0% | — | ||
| Q2 25 | 20.7% | -7.5% | ||
| Q1 25 | 7.1% | 12.2% | ||
| Q4 24 | 0.1% | 16.0% | ||
| Q3 24 | -7.9% | 13.8% | ||
| Q2 24 | -31.7% | 15.0% | ||
| Q1 24 | -127.1% | 22.1% |
| Q4 25 | 16.6% | 12.8% | ||
| Q3 25 | 39.5% | — | ||
| Q2 25 | 26.7% | -5.6% | ||
| Q1 25 | 20.0% | 7.1% | ||
| Q4 24 | 17.5% | 11.7% | ||
| Q3 24 | -6.7% | 11.6% | ||
| Q2 24 | -9.8% | 13.3% | ||
| Q1 24 | -142.5% | 16.2% |
| Q4 25 | $0.25 | $0.24 | ||
| Q3 25 | $0.50 | — | ||
| Q2 25 | $0.29 | $-0.11 | ||
| Q1 25 | $0.18 | $0.14 | ||
| Q4 24 | $1.23 | $0.22 | ||
| Q3 24 | $-0.05 | $0.21 | ||
| Q2 24 | $-0.05 | $0.26 | ||
| Q1 24 | $-1.77 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.4B | $2.0B |
| Total Assets | $1.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $172.9M | ||
| Q3 25 | $140.4M | — | ||
| Q2 25 | $162.3M | $162.2M | ||
| Q1 25 | $86.4M | $140.7M | ||
| Q4 24 | $79.6M | $177.5M | ||
| Q3 24 | $126.1M | $187.5M | ||
| Q2 24 | $421.1M | $152.9M | ||
| Q1 24 | $696.1M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $2.0B | ||
| Q4 24 | $964.8M | $2.1B | ||
| Q3 24 | $889.6M | $2.1B | ||
| Q2 24 | $845.3M | $2.1B | ||
| Q1 24 | $808.8M | $2.0B |
| Q4 25 | $1.5B | $2.5B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.1B | $2.6B | ||
| Q4 24 | $1.1B | $2.7B | ||
| Q3 24 | $983.1M | $2.7B | ||
| Q2 24 | $915.5M | $2.7B | ||
| Q1 24 | $864.9M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | — |
| Free Cash FlowOCF − Capex | $76.6M | — |
| FCF MarginFCF / Revenue | 28.3% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | — | ||
| Q3 25 | $78.2M | — | ||
| Q2 25 | $135.4M | $98.2M | ||
| Q1 25 | $10.5M | $41.1M | ||
| Q4 24 | $39.7M | $84.3M | ||
| Q3 24 | $63.5M | $63.9M | ||
| Q2 24 | $29.8M | $75.5M | ||
| Q1 24 | $3.7M | $81.0M |
| Q4 25 | $76.6M | — | ||
| Q3 25 | $65.9M | — | ||
| Q2 25 | $133.3M | $93.3M | ||
| Q1 25 | $6.0M | $31.0M | ||
| Q4 24 | $24.3M | $77.5M | ||
| Q3 24 | $46.8M | $54.7M | ||
| Q2 24 | $28.5M | $57.5M | ||
| Q1 24 | $228.0K | $64.5M |
| Q4 25 | 28.3% | — | ||
| Q3 25 | 28.6% | — | ||
| Q2 25 | 69.5% | 29.4% | ||
| Q1 25 | 3.7% | 9.8% | ||
| Q4 24 | 17.2% | 26.1% | ||
| Q3 24 | 41.4% | 18.9% | ||
| Q2 24 | 37.1% | 18.8% | ||
| Q1 24 | 0.3% | 21.3% |
| Q4 25 | 6.9% | — | ||
| Q3 25 | 5.3% | — | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.8% | 3.2% | ||
| Q4 24 | 10.9% | 2.3% | ||
| Q3 24 | 14.8% | 3.2% | ||
| Q2 24 | 1.7% | 5.9% | ||
| Q1 24 | 5.2% | 5.4% |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | 1.82× | ||
| Q4 24 | 1.61× | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
